STADA Arzneimittel AG — M&A Activity 2011

Nov 9, 2011

News Details

Ad-hoc | 9 November 2011 14:07

STADA: STADA signs contract on the purchase of a generics business in Switzerland

STADA Arzneimittel AG / Key word(s): Mergers & Acquisitions

09.11.2011 14:07

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Bad Vilbel, November 9, 2011 - STADA Arzneimittel AG and the shareholders
of Spirig Pharma AG, a Swiss pharmaceuticals company based in Egerkingen,
Canton Solothurn, have today, on November 9, 2011, signed a contract on the
purchase of Spirig's generics business including the respective sales
structures by STADA, after both companies had published the intended
transaction already on May 19, 2011 (see ad hoc release as of May 19, 2011,
published via DGAP).

The purchase price for this generics business totals approx. CHF 97 million
(at the current exchange rate approx. EUR 78 million) and also includes the
right to continue marketing the acquired products under the Spirig umbrella
brand. The acquired portfolio includes 56 prescription (RX) and 15
non-prescription (OTC) and discretionary prescription (OTX) products. With
regard to the acquired products STADA estimates the current annual sales
volume to be approx. CHF 42 million (at the current exchange rate approx.
EUR 34 million) and EBIDTA, adjusted to the business structure being spun
off, to be approx. CHF 9.5 million (at the current exchange rate approx.
EUR 7.7 million). The acquisition does not include any production
facilities.

The transaction is carried out under the usual execution terms as well as
on condition that Spirig had spun off the business to be acquired into a
separate independent business unit. Execution of the acquisition is planned
for the first quarter of 2012. Payment of the purchase price will be made
at the time of the execution. STADA will use cash on hand and existing free
credit lines to finance the acquisition.

Additional information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D -
61118 Bad Vilbel /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail:
communications@stada.de
Or visit us in the Internet at www.stada.com.

09.11.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart

End of Announcement DGAP News-Service

---